ID   TE2IP_HUMAN             Reviewed;         399 AA.
AC   Q9NYB0; B4DQN4; Q4W4Y2; Q8WYZ3; Q9NWR2;
DT   20-JUN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   28-JUN-2023, entry version 207.
DE   RecName: Full=Telomeric repeat-binding factor 2-interacting protein 1;
DE            Short=TERF2-interacting telomeric protein 1;
DE            Short=TRF2-interacting telomeric protein 1;
DE   AltName: Full=Dopamine receptor-interacting protein 5;
DE   AltName: Full=Repressor/activator protein 1 homolog;
DE            Short=RAP1 homolog;
DE            Short=hRap1;
GN   Name=TERF2IP; Synonyms=DRIP5, RAP1; ORFNames=PP8000;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=10850490; DOI=10.1016/s0092-8674(00)80858-2;
RA   Li B., Oestreich S., de Lange T.;
RT   "Identification of human RAP1: implications for telomere evolution.";
RL   Cell 101:471-483(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Lafuente M.J., Nasir J.;
RT   "Cloning and characterization of DRIP5, a new protein that specifically
RT   interacts with the D1 dopamine receptor.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H., Qiu X.,
RA   Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y., Shu H., Chen X.,
RA   Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S., Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ileal mucosa, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon, Lung, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   BIDIRECTIONAL PROMOTER WITH KARS1.
RX   PubMed=14659874; DOI=10.1016/j.gene.2003.08.026;
RA   Tan M., Wei C., Price C.M.;
RT   "The telomeric protein Rap1 is conserved in vertebrates and is expressed
RT   from a bidirectional promoter positioned between the Rap1 and KARS genes.";
RL   Gene 323:1-10(2003).
RN   [9]
RP   IDENTIFICATION IN THE SHELTERIN COMPLEX.
RX   PubMed=15316005; DOI=10.1074/jbc.m409047200;
RA   Ye J.Z.-S., Donigian J.R., van Overbeek M., Loayza D., Luo Y.,
RA   Krutchinsky A.N., Chait B.T., de Lange T.;
RT   "TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on
RT   telomeres.";
RL   J. Biol. Chem. 279:47264-47271(2004).
RN   [10]
RP   IDENTIFICATION IN THE SHELTERIN COMPLEX.
RX   PubMed=15383534; DOI=10.1074/jbc.m409293200;
RA   Liu D., O'Connor M.S., Qin J., Songyang Z.;
RT   "Telosome, a mammalian telomere-associated complex formed by multiple
RT   telomeric proteins.";
RL   J. Biol. Chem. 279:51338-51342(2004).
RN   [11]
RP   FUNCTION OF THE SHELTERIN COMPLEX.
RX   PubMed=16166375; DOI=10.1101/gad.1346005;
RA   de Lange T.;
RT   "Shelterin: the protein complex that shapes and safeguards human
RT   telomeres.";
RL   Genes Dev. 19:2100-2110(2005).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-156 AND SER-203, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36; SER-154 AND SER-203, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   INTERACTION WITH SLX4.
RX   PubMed=19596235; DOI=10.1016/j.cell.2009.06.030;
RA   Svendsen J.M., Smogorzewska A., Sowa M.E., O'Connell B.C., Gygi S.P.,
RA   Elledge S.J., Harper J.W.;
RT   "Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is
RT   required for DNA repair.";
RL   Cell 138:63-77(2009).
RN   [17]
RP   FUNCTION.
RX   PubMed=19763083; DOI=10.1038/emboj.2009.275;
RA   Sarthy J., Bae N.S., Scrafford J., Baumann P.;
RT   "Human RAP1 inhibits non-homologous end joining at telomeres.";
RL   EMBO J. 28:3390-3399(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-154 AND SER-203, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36; SER-154 AND SER-203, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36; SER-43; SER-154; SER-203
RP   AND SER-206, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-203, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-240, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [25]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-114; LYS-212 AND LYS-240, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [26]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-114; LYS-194; LYS-208; LYS-212;
RP   LYS-240 AND LYS-372, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [27]
RP   STRUCTURE BY NMR OF 132-190.
RX   PubMed=11545594; DOI=10.1006/jmbi.2001.4924;
RA   Hanaoka S., Nagadoi A., Yoshimura S., Aimoto S., Li B., de Lange T.,
RA   Nishimura Y.;
RT   "NMR structure of the hRap1 Myb motif reveals a canonical three-helix
RT   bundle lacking the positive surface charge typical of Myb DNA-binding
RT   domains.";
RL   J. Mol. Biol. 312:167-175(2001).
CC   -!- FUNCTION: Acts both as a regulator of telomere function and as a
CC       transcription regulator. Involved in the regulation of telomere length
CC       and protection as a component of the shelterin complex (telosome). In
CC       contrast to other components of the shelterin complex, it is
CC       dispensible for telomere capping and does not participate in the
CC       protection of telomeres against non-homologous end-joining (NHEJ)-
CC       mediated repair. Instead, it is required to negatively regulate
CC       telomere recombination and is essential for repressing homology-
CC       directed repair (HDR), which can affect telomere length. Does not bind
CC       DNA directly: recruited to telomeric double-stranded 5'-TTAGGG-3'
CC       repeats via its interaction with TERF2. Independently of its function
CC       in telomeres, also acts as a transcription regulator: recruited to
CC       extratelomeric 5'-TTAGGG-3' sites via its association with TERF2 or
CC       other factors, and regulates gene expression. When cytoplasmic,
CC       associates with the I-kappa-B-kinase (IKK) complex and acts as a
CC       regulator of the NF-kappa-B signaling by promoting IKK-mediated
CC       phosphorylation of RELA/p65, leading to activate expression of NF-
CC       kappa-B target genes. {ECO:0000269|PubMed:16166375,
CC       ECO:0000269|PubMed:19763083}.
CC   -!- SUBUNIT: Associates with the I-kappa-B-kinase (IKK) core complex,
CC       composed of CHUK, IKBKB and IKBKG (By similarity). Homodimer. Component
CC       of the shelterin complex (telosome) composed of TERF1, TERF2, TINF2,
CC       TERF2IP ACD and POT1. Interacts with TERF2; the interaction is direct.
CC       Does not interact with TERF1. Interacts with SLX4/BTBD12. {ECO:0000250,
CC       ECO:0000269|PubMed:15316005, ECO:0000269|PubMed:15383534,
CC       ECO:0000269|PubMed:19596235}.
CC   -!- INTERACTION:
CC       Q9NYB0; Q13155: AIMP2; NbExp=2; IntAct=EBI-750109, EBI-745226;
CC       Q9NYB0; P14550: AKR1A1; NbExp=2; IntAct=EBI-750109, EBI-372388;
CC       Q9NYB0; O60218: AKR1B10; NbExp=2; IntAct=EBI-750109, EBI-1572139;
CC       Q9NYB0; O95154: AKR7A3; NbExp=2; IntAct=EBI-750109, EBI-748869;
CC       Q9NYB0; P31749: AKT1; NbExp=2; IntAct=EBI-750109, EBI-296087;
CC       Q9NYB0; Q9NWV8: BABAM1; NbExp=2; IntAct=EBI-750109, EBI-745725;
CC       Q9NYB0; Q9BQE9: BCL7B; NbExp=2; IntAct=EBI-750109, EBI-2560588;
CC       Q9NYB0; Q8IYL3: C1orf174; NbExp=2; IntAct=EBI-750109, EBI-715898;
CC       Q9NYB0; Q9NZ63: C9orf78; NbExp=2; IntAct=EBI-750109, EBI-2557577;
CC       Q9NYB0; P27482: CALML3; NbExp=2; IntAct=EBI-750109, EBI-747537;
CC       Q9NYB0; Q9UQN3: CHMP2B; NbExp=2; IntAct=EBI-750109, EBI-718324;
CC       Q9NYB0; Q14019: COTL1; NbExp=2; IntAct=EBI-750109, EBI-79926;
CC       Q9NYB0; Q96FN4: CPNE2; NbExp=2; IntAct=EBI-750109, EBI-7097057;
CC       Q9NYB0; P46108: CRK; NbExp=2; IntAct=EBI-750109, EBI-886;
CC       Q9NYB0; Q13363: CTBP1; NbExp=2; IntAct=EBI-750109, EBI-908846;
CC       Q9NYB0; Q92620: DHX38; NbExp=2; IntAct=EBI-750109, EBI-1043041;
CC       Q9NYB0; Q8N8S7: ENAH; NbExp=2; IntAct=EBI-750109, EBI-2834410;
CC       Q9NYB0; Q8TE68: EPS8L1; NbExp=2; IntAct=EBI-750109, EBI-7487998;
CC       Q9NYB0; P12104: FABP2; NbExp=2; IntAct=EBI-750109, EBI-3905109;
CC       Q9NYB0; Q13069: GAGE5; NbExp=2; IntAct=EBI-750109, EBI-745702;
CC       Q9NYB0; Q92917: GPKOW; NbExp=2; IntAct=EBI-750109, EBI-746309;
CC       Q9NYB0; Q16775: HAGH; NbExp=2; IntAct=EBI-750109, EBI-3905342;
CC       Q9NYB0; O15347: HMGB3; NbExp=2; IntAct=EBI-750109, EBI-2214136;
CC       Q9NYB0; O00479: HMGN4; NbExp=2; IntAct=EBI-750109, EBI-2867693;
CC       Q9NYB0; P61978: HNRNPK; NbExp=2; IntAct=EBI-750109, EBI-304185;
CC       Q9NYB0; P18510: IL1RN; NbExp=2; IntAct=EBI-750109, EBI-1026330;
CC       Q9NYB0; Q9NS86: LANCL2; NbExp=2; IntAct=EBI-750109, EBI-2510837;
CC       Q9NYB0; Q96A72: MAGOHB; NbExp=2; IntAct=EBI-750109, EBI-746778;
CC       Q9NYB0; P49736: MCM2; NbExp=2; IntAct=EBI-750109, EBI-374819;
CC       Q9NYB0; Q9UKD2: MRTO4; NbExp=2; IntAct=EBI-750109, EBI-1046493;
CC       Q9NYB0; P80297: MT1X; NbExp=2; IntAct=EBI-750109, EBI-11308402;
CC       Q9NYB0; P25713: MT3; NbExp=2; IntAct=EBI-750109, EBI-8084264;
CC       Q9NYB0; P49321: NASP; NbExp=2; IntAct=EBI-750109, EBI-716205;
CC       Q9NYB0; O95848: NUDT14; NbExp=2; IntAct=EBI-750109, EBI-536866;
CC       Q9NYB0; Q6ZVK8: NUDT18; NbExp=2; IntAct=EBI-750109, EBI-740486;
CC       Q9NYB0; Q14980: NUMA1; NbExp=2; IntAct=EBI-750109, EBI-521611;
CC       Q9NYB0; Q9NZT2: OGFR; NbExp=2; IntAct=EBI-750109, EBI-1044212;
CC       Q9NYB0; Q96E09: PABIR1; NbExp=2; IntAct=EBI-750109, EBI-9355758;
CC       Q9NYB0; Q8WW12: PCNP; NbExp=2; IntAct=EBI-750109, EBI-10972020;
CC       Q9NYB0; P48539: PCP4; NbExp=2; IntAct=EBI-750109, EBI-4287270;
CC       Q9NYB0; Q15121: PEA15; NbExp=2; IntAct=EBI-750109, EBI-714410;
CC       Q9NYB0; O95336: PGLS; NbExp=2; IntAct=EBI-750109, EBI-11307753;
CC       Q9NYB0; P28340: POLD1; NbExp=2; IntAct=EBI-750109, EBI-716569;
CC       Q9NYB0; Q5H9R7: PPP6R3; NbExp=2; IntAct=EBI-750109, EBI-355498;
CC       Q9NYB0; Q9BXM0: PRX; NbExp=2; IntAct=EBI-750109, EBI-1753064;
CC       Q9NYB0; P06454: PTMA; NbExp=2; IntAct=EBI-750109, EBI-2682091;
CC       Q9NYB0; P47224: RABIF; NbExp=2; IntAct=EBI-750109, EBI-713992;
CC       Q9NYB0; O75884: RBBP9; NbExp=2; IntAct=EBI-750109, EBI-11310604;
CC       Q9NYB0; Q96B86: RGMA; NbExp=2; IntAct=EBI-750109, EBI-722102;
CC       Q9NYB0; Q9BUL9: RPP25; NbExp=2; IntAct=EBI-750109, EBI-366570;
CC       Q9NYB0; P25815: S100P; NbExp=2; IntAct=EBI-750109, EBI-743700;
CC       Q9NYB0; Q96I15: SCLY; NbExp=2; IntAct=EBI-750109, EBI-2823066;
CC       Q9NYB0; Q8IY92: SLX4; NbExp=4; IntAct=EBI-750109, EBI-2370740;
CC       Q9NYB0; Q8TAQ2: SMARCC2; NbExp=2; IntAct=EBI-750109, EBI-357418;
CC       Q9NYB0; P37837: TALDO1; NbExp=2; IntAct=EBI-750109, EBI-1056712;
CC       Q9NYB0; O75347: TBCA; NbExp=2; IntAct=EBI-750109, EBI-2686341;
CC       Q9NYB0; Q15554: TERF2; NbExp=36; IntAct=EBI-750109, EBI-706637;
CC       Q9NYB0; Q9BSI4-3: TINF2; NbExp=3; IntAct=EBI-750109, EBI-717418;
CC       Q9NYB0; O14604: TMSB4Y; NbExp=2; IntAct=EBI-750109, EBI-751196;
CC       Q9NYB0; Q5JTV8: TOR1AIP1; NbExp=2; IntAct=EBI-750109, EBI-2559665;
CC       Q9NYB0; Q9Y5U2: TSSC4; NbExp=2; IntAct=EBI-750109, EBI-717229;
CC       Q9NYB0; Q6IBS0: TWF2; NbExp=2; IntAct=EBI-750109, EBI-722204;
CC       Q9NYB0; P09936: UCHL1; NbExp=2; IntAct=EBI-750109, EBI-714860;
CC       Q9NYB0; Q14135: VGLL4; NbExp=2; IntAct=EBI-750109, EBI-5278589;
CC       Q9NYB0; P61964: WDR5; NbExp=2; IntAct=EBI-750109, EBI-540834;
CC       Q9NYB0; Q96GT9: XAGE2; NbExp=2; IntAct=EBI-750109, EBI-750167;
CC       Q9NYB0; P12956: XRCC6; NbExp=3; IntAct=EBI-750109, EBI-353208;
CC       Q9NYB0; Q96IQ9: ZNF414; NbExp=2; IntAct=EBI-750109, EBI-744257;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:Q91VL8}. Cytoplasm
CC       {ECO:0000250|UniProtKB:Q91VL8}. Chromosome
CC       {ECO:0000250|UniProtKB:Q91VL8}. Chromosome, telomere
CC       {ECO:0000250|UniProtKB:Q91VL8}. Note=Associates with chromosomes, both
CC       at telomeres and in extratelomeric sites. Also exists as a cytoplasmic
CC       form, where it associates with the IKK complex.
CC       {ECO:0000250|UniProtKB:Q91VL8}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Highly expressed.
CC   -!- MISCELLANEOUS: Shares a bidirectional promoter with KARS1.
CC       {ECO:0000305|PubMed:14659874}.
CC   -!- SIMILARITY: Belongs to the RAP1 family. {ECO:0000305}.
CC   -!- CAUTION: Was reported to participate in the protection of telomeres
CC       against non-homologous end-joining (NHEJ)-mediated repair in the
CC       absence of TERF2 (PubMed:19763083). However, this probably does not
CC       corresponds to its primary function and experiments in mouse showed
CC       that it is dispensible for such process and is required for repression
CC       of homology-directed repair (HDR). {ECO:0000305|PubMed:19763083}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAL55783.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAA91317.1; Type=Erroneous termination; Note=Truncated C-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAG60996.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF262988; AAF72711.1; -; mRNA.
DR   EMBL; AF250393; AAQ14259.1; -; mRNA.
DR   EMBL; AF289599; AAL55783.1; ALT_FRAME; mRNA.
DR   EMBL; AK000669; BAA91317.1; ALT_SEQ; mRNA.
DR   EMBL; AK298880; BAG60996.1; ALT_INIT; mRNA.
DR   EMBL; AC025287; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471114; EAW95616.1; -; Genomic_DNA.
DR   EMBL; CH471114; EAW95618.1; -; Genomic_DNA.
DR   EMBL; BC004465; AAH04465.1; -; mRNA.
DR   EMBL; BC005841; AAH05841.1; -; mRNA.
DR   EMBL; BC022428; AAH22428.1; -; mRNA.
DR   EMBL; BC078171; AAH78171.1; -; mRNA.
DR   CCDS; CCDS32491.1; -.
DR   RefSeq; NP_061848.2; NM_018975.3.
DR   PDB; 1FEX; NMR; -; A=132-190.
DR   PDB; 3K6G; X-ray; 1.95 A; A/B/C=303-399.
DR   PDB; 4RQI; X-ray; 2.44 A; E/F/G/H=89-106.
DR   PDB; 7OZ0; NMR; -; A=1-114.
DR   PDBsum; 1FEX; -.
DR   PDBsum; 3K6G; -.
DR   PDBsum; 4RQI; -.
DR   PDBsum; 7OZ0; -.
DR   AlphaFoldDB; Q9NYB0; -.
DR   BMRB; Q9NYB0; -.
DR   SMR; Q9NYB0; -.
DR   BioGRID; 119942; 614.
DR   ComplexPortal; CPX-152; Shelterin complex.
DR   CORUM; Q9NYB0; -.
DR   DIP; DIP-34868N; -.
DR   IntAct; Q9NYB0; 161.
DR   MINT; Q9NYB0; -.
DR   STRING; 9606.ENSP00000300086; -.
DR   BindingDB; Q9NYB0; -.
DR   ChEMBL; CHEMBL3751647; -.
DR   GlyCosmos; Q9NYB0; 1 site, 1 glycan.
DR   GlyGen; Q9NYB0; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q9NYB0; -.
DR   PhosphoSitePlus; Q9NYB0; -.
DR   BioMuta; TERF2IP; -.
DR   DMDM; 21542267; -.
DR   EPD; Q9NYB0; -.
DR   jPOST; Q9NYB0; -.
DR   MassIVE; Q9NYB0; -.
DR   MaxQB; Q9NYB0; -.
DR   PaxDb; Q9NYB0; -.
DR   PeptideAtlas; Q9NYB0; -.
DR   ProteomicsDB; 83206; -.
DR   Antibodypedia; 1877; 566 antibodies from 42 providers.
DR   DNASU; 54386; -.
DR   Ensembl; ENST00000300086.5; ENSP00000300086.4; ENSG00000166848.7.
DR   GeneID; 54386; -.
DR   KEGG; hsa:54386; -.
DR   MANE-Select; ENST00000300086.5; ENSP00000300086.4; NM_018975.4; NP_061848.2.
DR   UCSC; uc002fet.3; human.
DR   AGR; HGNC:19246; -.
DR   CTD; 54386; -.
DR   DisGeNET; 54386; -.
DR   GeneCards; TERF2IP; -.
DR   HGNC; HGNC:19246; TERF2IP.
DR   HPA; ENSG00000166848; Low tissue specificity.
DR   MalaCards; TERF2IP; -.
DR   MIM; 605061; gene.
DR   neXtProt; NX_Q9NYB0; -.
DR   OpenTargets; ENSG00000166848; -.
DR   Orphanet; 618; Familial melanoma.
DR   PharmGKB; PA134976325; -.
DR   VEuPathDB; HostDB:ENSG00000166848; -.
DR   eggNOG; ENOG502RPXS; Eukaryota.
DR   GeneTree; ENSGT00390000005351; -.
DR   HOGENOM; CLU_028192_0_0_1; -.
DR   InParanoid; Q9NYB0; -.
DR   OMA; MEKFAVD; -.
DR   OrthoDB; 2920206at2759; -.
DR   PhylomeDB; Q9NYB0; -.
DR   TreeFam; TF332348; -.
DR   PathwayCommons; Q9NYB0; -.
DR   Reactome; R-HSA-110328; Recognition and association of DNA glycosylase with site containing an affected pyrimidine.
DR   Reactome; R-HSA-110329; Cleavage of the damaged pyrimidine.
DR   Reactome; R-HSA-110330; Recognition and association of DNA glycosylase with site containing an affected purine.
DR   Reactome; R-HSA-110331; Cleavage of the damaged purine.
DR   Reactome; R-HSA-1221632; Meiotic synapsis.
DR   Reactome; R-HSA-171306; Packaging Of Telomere Ends.
DR   Reactome; R-HSA-171319; Telomere Extension By Telomerase.
DR   Reactome; R-HSA-174411; Polymerase switching on the C-strand of the telomere.
DR   Reactome; R-HSA-174414; Processive synthesis on the C-strand of the telomere.
DR   Reactome; R-HSA-174417; Telomere C-strand (Lagging Strand) Synthesis.
DR   Reactome; R-HSA-174430; Telomere C-strand synthesis initiation.
DR   Reactome; R-HSA-174437; Removal of the Flap Intermediate from the C-strand.
DR   Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; R-HSA-9670095; Inhibition of DNA recombination at telomere.
DR   SignaLink; Q9NYB0; -.
DR   SIGNOR; Q9NYB0; -.
DR   BioGRID-ORCS; 54386; 23 hits in 1161 CRISPR screens.
DR   ChiTaRS; TERF2IP; human.
DR   EvolutionaryTrace; Q9NYB0; -.
DR   GeneWiki; TERF2IP; -.
DR   GenomeRNAi; 54386; -.
DR   Pharos; Q9NYB0; Tchem.
DR   PRO; PR:Q9NYB0; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q9NYB0; protein.
DR   Bgee; ENSG00000166848; Expressed in middle temporal gyrus and 209 other tissues.
DR   ExpressionAtlas; Q9NYB0; baseline and differential.
DR   Genevisible; Q9NYB0; HS.
DR   GO; GO:0000781; C:chromosome, telomeric region; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:CAFA.
DR   GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0000228; C:nuclear chromosome; TAS:ProtInc.
DR   GO; GO:0000783; C:nuclear telomere cap complex; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0070187; C:shelterin complex; IDA:BHF-UCL.
DR   GO; GO:0098505; F:G-rich strand telomeric DNA binding; IDA:BHF-UCL.
DR   GO; GO:0019902; F:phosphatase binding; IPI:CAFA.
DR   GO; GO:0042162; F:telomeric DNA binding; IDA:BHF-UCL.
DR   GO; GO:0048239; P:negative regulation of DNA recombination at telomere; ISS:UniProtKB.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IMP:CAFA.
DR   GO; GO:0032205; P:negative regulation of telomere maintenance; IDA:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:1901224; P:positive regulation of NIK/NF-kappaB signaling; IMP:CAFA.
DR   GO; GO:0032206; P:positive regulation of telomere maintenance; NAS:ComplexPortal.
DR   GO; GO:0031848; P:protection from non-homologous end joining at telomere; IMP:BHF-UCL.
DR   GO; GO:0070198; P:protein localization to chromosome, telomeric region; IMP:BHF-UCL.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:CAFA.
DR   GO; GO:0010569; P:regulation of double-strand break repair via homologous recombination; ISS:UniProtKB.
DR   GO; GO:0032204; P:regulation of telomere maintenance; IMP:BHF-UCL.
DR   GO; GO:0016233; P:telomere capping; IDA:ComplexPortal.
DR   GO; GO:0000723; P:telomere maintenance; IDA:BHF-UCL.
DR   GO; GO:0007004; P:telomere maintenance via telomerase; TAS:ProtInc.
DR   GO; GO:0010833; P:telomere maintenance via telomere lengthening; ISS:UniProtKB.
DR   CDD; cd11655; rap1_myb-like; 1.
DR   CDD; cd11653; rap1_RCT; 1.
DR   Gene3D; 1.10.10.2170; -; 1.
DR   Gene3D; 3.40.50.10190; BRCT domain; 1.
DR   Gene3D; 1.10.10.60; Homeodomain-like; 1.
DR   InterPro; IPR001357; BRCT_dom.
DR   InterPro; IPR036420; BRCT_dom_sf.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR021661; Rap1_C.
DR   InterPro; IPR038104; Rap1_C_sf.
DR   InterPro; IPR015010; Rap1_Myb_dom.
DR   InterPro; IPR039595; TE2IP/Rap1.
DR   PANTHER; PTHR16466; TELOMERE REPEAT-BINDING FACTOR 2-INTERACTING PROTEIN 1; 1.
DR   PANTHER; PTHR16466:SF6; TELOMERIC REPEAT-BINDING FACTOR 2-INTERACTING PROTEIN 1; 1.
DR   Pfam; PF16589; BRCT_2; 1.
DR   Pfam; PF08914; Myb_DNA-bind_2; 1.
DR   Pfam; PF11626; Rap1_C; 1.
DR   SUPFAM; SSF46689; Homeodomain-like; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Chromosome; Cytoplasm;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Reference proteome; Telomere;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   CHAIN           2..399
FT                   /note="Telomeric repeat-binding factor 2-interacting
FT                   protein 1"
FT                   /id="PRO_0000197126"
FT   DOMAIN          78..101
FT                   /note="BRCT"
FT   DOMAIN          128..188
FT                   /note="Myb-like"
FT   REGION          104..132
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          196..244
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          264..311
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           383..399
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        208..237
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        264..283
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        284..306
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         36
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         43
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         154
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         156
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243"
FT   MOD_RES         203
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         206
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        114
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        194
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        208
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        212
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        240
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        372
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VARIANT         324
FT                   /note="K -> E (in dbSNP:rs4888444)"
FT                   /id="VAR_050195"
FT   CONFLICT        83
FT                   /note="Y -> H (in Ref. 4; BAA91317)"
FT                   /evidence="ECO:0000305"
FT   HELIX           93..97
FT                   /evidence="ECO:0007829|PDB:4RQI"
FT   HELIX           138..150
FT                   /evidence="ECO:0007829|PDB:1FEX"
FT   TURN            155..159
FT                   /evidence="ECO:0007829|PDB:1FEX"
FT   HELIX           162..169
FT                   /evidence="ECO:0007829|PDB:1FEX"
FT   STRAND          172..174
FT                   /evidence="ECO:0007829|PDB:1FEX"
FT   HELIX           178..187
FT                   /evidence="ECO:0007829|PDB:1FEX"
FT   HELIX           308..324
FT                   /evidence="ECO:0007829|PDB:3K6G"
FT   HELIX           329..338
FT                   /evidence="ECO:0007829|PDB:3K6G"
FT   TURN            339..341
FT                   /evidence="ECO:0007829|PDB:3K6G"
FT   HELIX           343..352
FT                   /evidence="ECO:0007829|PDB:3K6G"
FT   HELIX           364..370
FT                   /evidence="ECO:0007829|PDB:3K6G"
FT   HELIX           375..385
FT                   /evidence="ECO:0007829|PDB:3K6G"
FT   HELIX           387..397
FT                   /evidence="ECO:0007829|PDB:3K6G"
SQ   SEQUENCE   399 AA;  44260 MW;  EAA615777F9D3D3D CRC64;
     MAEAMDLGKD PNGPTHSSTL FVRDDGSSMS FYVRPSPAKR RLSTLILHGG GTVCRVQEPG
     AVLLAQPGEA LAEASGDFIS TQYILDCVER NERLELEAYR LGPASAADTG SEAKPGALAE
     GAAEPEPQRH AGRIAFTDAD DVAILTYVKE NARSPSSVTG NALWKAMEKS SLTQHSWQSL
     KDRYLKHLRG QEHKYLLGDA PVSPSSQKLK RKAEEDPEAA DSGEPQNKRT PDLPEEEYVK
     EEIQENEEAV KKMLVEATRE FEEVVVDESP PDFEIHITMC DDDPPTPEED SETQPDEEEE
     EEEEKVSQPE VGAAIKIIRQ LMEKFNLDLS TVTQAFLKNS GELEATSAFL ASGQRADGYP
     IWSRQDDIDL QKDDEDTREA LVKKFGAQNV ARRIEFRKK
//
